Solid tumours have a dirty secret: at their core, they're a mess.
The interior of a large tumour is poorly vascularised — blood vessels can't properly penetrate it. This means the tumour's heart is starved of oxygen, acidic, and crammed with metabolic waste products.
For conventional medicine, this is a problem. Chemotherapy drugs need blood flow to reach their target. Radiation is less effective in low-oxygen environments. The hypoxic tumour core is where treatment often fails to penetrate — and where cancer cells can hide, survive, and eventually seed new growth.
But researchers have now had an idea that turns this weakness into a target.
**If Tumours Have No Oxygen — Send in Bacteria That Don't Need It**
Anaerobic bacteria are microorganisms that thrive in the absence of oxygen. Many of them are harmless — or can be engineered to be harmless — in normal tissue, where oxygen levels keep their growth in check. But place them in a low-oxygen environment and they thrive.
The inside of a solid tumour is, for an anaerobic bacterium, something close to paradise.
Researchers are now exploiting exactly this biological quirk. By engineering anaerobic bacteria to preferentially colonise the hypoxic cores of tumours — and programming those bacteria to release therapeutic payloads, trigger immune responses, or directly break down tumour tissue — scientists are developing what amount to **living, self-directed cancer treatments**.
**The Engineered Approach**
The bacteria used in this research are carefully modified. They're designed to:
🎯 **Home in on tumour tissue** — exploiting the chemical gradients around hypoxic cores to navigate to their target 💊 **Release therapeutic molecules** once inside — from tumour-attacking toxins to immune system activators that call in the body's own defences 🛡️ **Self-limit in normal tissue** — remaining inactive or dying off in oxygenated environments so they don't spread through healthy organs
Because anaerobic bacteria naturally concentrate in the oxygen-deprived regions that drugs struggle to reach, they can deliver their payload precisely where it's needed most.
**A Century-Old Idea, Transformed**
This approach — sometimes called **bacterial cancer therapy** or **microbial oncology** — has echoes going back over a century. In the 1890s, physician William Coley noticed that cancer patients who developed certain bacterial infections sometimes experienced unexpected tumour regression. The mechanism wasn't understood, but the observation planted a seed.
Modern genetic engineering has transformed that seed into something far more precise. Today's engineered bacteria can be programmed with specific genetic circuits — gene sequences that activate only under certain conditions (like low oxygen), producing therapeutic molecules on demand. The bacteria become programmable biological machines, targeted to the precise environment where they can do the most good.
**Results and Outlook**
In preclinical studies, bacteria-based tumour treatments have shown complete tumour elimination in animal models for several cancer types. The approach is now being refined for human trials, with particular interest in **solid tumours** — cancers of the liver, pancreas, colon, and lung — where hypoxic cores are most problematic and conventional treatments are most limited.
The field is still early, and translating any therapy from mice to humans requires clearing significant safety and efficacy hurdles. But the elegance of the concept is undeniable: using a cancer's own anatomical feature — the hostile, airless void at its heart — as the mechanism of its destruction.
Where drugs fail to penetrate, bacteria find a way in. And once they're in, they get to work.
The tumour's greatest fortress may turn out to be its greatest vulnerability. 🦠🧬🎯
*Source: ScienceDaily · Cancer Research (February 2026)*